The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy ...
Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy ...
After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's UCB is getting | The agreement fulfills ...
UCB has announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, ...
Acquisition builds on UCB’s 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies.Lead investigational asset, NRTX-1001, a ...
The takeover – which, if completed, will be the third acquisition for UCB this decade – involves an upfront payment of $650 ...
SHANGHAI, March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured ...
PHOENIX — Mayo Clinic is taking epilepsy research in a bold new direction, exploring treatment approaches to help patients living with the most severe and difficult-to-treat forms of epilepsy. About ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results